Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 157 (1) , 268-279
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81672510)
This publication has 36 references indexed in Scilit:
- Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene RegulationJournal of Biological Chemistry, 2015
- The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: A survival mechanism in methotrexate-resistant choriocarcinoma cellsExperimental Cell Research, 2015
- Individualization of Treatments with Drugs Metabolized by CES1: Combining Genetics and MetabolomicsPharmacogenomics, 2015
- Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cellsInternational Journal of Oncology, 2014
- AKR1C3 Overexpression Mediates Methotrexate Resistance in Choriocarcinoma CellsInternational Journal of Medical Sciences, 2014
- Lutein Protects against Methotrexate-Induced and Reactive Oxygen Species-Mediated Apoptotic Cell Injury of IEC-6 CellsPLOS ONE, 2013
- Autophagy induced by valproic acid is associated with oxidative stress in glioma cell linesNeuro-Oncology, 2009
- An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell LinesCancer Research, 2004
- The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen speciesBritish Journal of Pharmacology, 2003
- EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)Gynecologic Oncology, 1988